Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes

Clin Cancer Res. 2023 May 1;29(9):1648-1650. doi: 10.1158/1078-0432.CCR-23-0018.

Abstract

Isocitrate dehydrogenase 1-mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radioresistance for IDH1m gliomas, and pharmacologic targeting of this pathway may heighten radiotherapy-induced tumor response, providing a prospect of improved clinical outcomes. See related article by Carney et al., p. 1763.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / metabolism
  • Brain Neoplasms* / radiotherapy
  • Glioma* / genetics
  • Glioma* / metabolism
  • Glioma* / radiotherapy
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Isocitrate Dehydrogenase / metabolism
  • MYND Domains
  • Mutation

Substances

  • Isocitrate Dehydrogenase
  • IDH1 protein, human